Pentixapharm Gets Ethics Approval for PANDA Phase 3 Study

The PANDA Phase 3 protocol and participant consent documents received approval from a central U.S. ethics committee. First patient enrollment is expected in Q1 2027, and the study is designed to enroll approximately 325 patients.